Adefovir Dipivoxil, Tenofovir Disoproxil Fumarate or Lamivudine; Which is Suitable Monotherapy Medication in the Patients with Chronic Hepatitis B Virus Infection? One Year Experience

Introduction: The hepatitis B virus infection is responsible for more than one million deaths all over the world. This study design is to compare the efficacy of Lamivudine (LAM), Adefovir Dipivoxil (ADV) or Tenofovir Disoproxil Fumarate (TDF) monotherapy in chronically infected hepatitis B patients. Methods: We design a prospective cohort study and select patients who were under treatment with TDF (300mg/day), ADV (10mg/day) and LAM (100mg/day). After matching patient's primary data and on base of our inclusion and exclusion criteria; 19, 20 and 19 patients were enrolled in TDF, LAM and ADV groups, respectively. Then, we evaluated patients at 6 and 12 month after treatment. Results: Patents primary data was closely matched. After 6 month medication, ALT level in 7 patients (36.8%), 12 patients (60%) and 6 patients (31.6%) of TDF, LAM and ADV groups were back to normal range, respectively (P>0.05). All drugs significantly decrease ALT level after 6 month therapy (P 0.05). Finally, response to treatment was observed in 5 patients (45.5%), 7 patients (35%) and 2 patients (10.5%) of TDF, LAM and ADV group, respectively (P>0.05).